Liver metastases from pancreatic adenocarcinoma

Jin He, David Cosgrove, Joseph M. Herman, Timothy M. Pawlik

Research output: Chapter in Book/Report/Conference proceedingChapter


Pancreatic cancer is the fourth leading cause of cancer-related death in Europe and the United States (Malvezzi et al Ann Oncol 24(3):792 - 800, 2013). At the time of diagnosis, approximately half of patients with pancreatic adenocarcinoma will have synchronous metastasis. Patients with metastatic pancreatic cancer generally have a median survival of 6 months and a 5-year survival of about 2 - 5 %. The liver is a frequent site of metastasis as pancreatic adenocarcinoma can metastasize to the liver through portal venous or intra-abdominal lymphatic drainage. For example, in a study from Johns Hopkins Hospital, among 838 patients with pancreatic adenocarcinoma who underwent a pancreatectomy, 46 % subsequently developed metachronous liver metastasis. Of note, among those patients with pancreatic cancer metastatic to the liver, 60 % had isolated liver metastasis without extrahepatic recurrence at the time of last follow-up.

Original languageEnglish (US)
Title of host publicationNoncolorectal, Nonneuroendocrine Liver Metastases
Subtitle of host publicationDiagnosis and Current Therapies
PublisherSpringer International Publishing
Number of pages15
ISBN (Electronic)9783319092935
ISBN (Print)9783319092928
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Liver metastases from pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this